In the Spotlight...

ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer

Hsieh et al. showed CD47, the receptor for SIRPα – the don’t eat me signal – is upregulated on a variety of human solid tumor lines and rectal cancer biopsies, particularly from patients with poor res...

A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma

Using scATACseq to probe the landscape of infiltrating T cells in RCC (a tumor where high T cell infiltration associates with poor survival), Kourtis, Wang, and Wang et al. demonstrated that the chrom...

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Reijers et al. reported on the feasibility, safety, and efficacy of using the response to neoadjuvant ipilimumab plus nivolumab to direct further therapy in patients with stage III melanoma. In the PR...

Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity

Yang and Jin et al. demonstrated that, compared to female, male CD8+ T cells exhibited impaired effector and stem cell-like properties, leading to sex-biased antitumor immunity during cancer progressi...

Previous Digests

Identifying biomarkers for chemo-immunotherapy outcomes in PDAC

June 15, 2022

Pancreatic ductal adenocarcinoma (PDAC) responds notoriously poorly to treatment, including immune checkpoint blockade; combination chemotherapies are the standard of care, but clinical responses remain deficient. Recently, studies in murine PDAC models improved treatment efficacy by combining chemotherapy with a...

New vaccine attracts T and NK cells to uninviting tumors

June 8, 2022

Since most cancer vaccines target antigens presented by MHC, the efficacy of such vaccines can be significantly impacted by the downregulation of antigen processing and presentation by tumor cells, which is a common feature in many cancer types. To...

Dressed to kill: wearing tumor cell-derived pMHC helps DCs prime T cell responses

June 1, 2022

Antigen cross-presentation by dendritic cells (DCs) is traditionally thought of as the primary mechanism underlying CD8+ T cell priming against tumors, but evidence of an alternative antigen presentation pathway, DC cross-dressing with tumor-derived peptide:MHC-I, has also been observed. In...

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Lespinasse-Llambi

Gaelle Lespinasse-Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Samuel (Sandy) Goldman

Samuel (Sandy) Goldman

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Elaine Yee Lin Chung

Elaine Yee Lin Chung

Nathan Suek

Nathan Suek

Margot O'Toole

Margot O'Toole

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.